clinical trial · NCT06868667
Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
GlaxoSmithKline·phase3·active not recruiting·n = 24
Multiple MyelomaBelantamab mafodotinDaratumumabBortezomibDexamethasone
brief summary
This study is designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone versus daratumumab in combination with bortezomib/dexamethasone in the Japanese participants with relapsed refractory multiple myeloma.
started
Jul 28, 2021
primary completion
Apr 3, 2024
completion
Jun 30, 2028
last updated
Apr 23, 2026
official title
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol